Proprium Biotech Closes ￥10M Series A Funding Round
According to VCBeat, Hangzhou Proprium Biotech Co., Ltd. ("Proprium Biotech") has completed its Series A financing of tens of millions, led by Neovision Capital. Proceeds from this round will mainly be used for the marketing of Proprium Biotech's core product, the chitinase-3-like protein 1 (CHI3L1), and the expansion of its domestic and overseas sale channels. This financing will be a great support for Proprium Biotech's vision of "free the world from serious liver diseases".
Proprium Biotech is a leader in the diagnosis and management of liver diseases with several issued patents and pending applications in China, Japan and other countries. The company has successively developed several exclusive products in China, including CHI3L1, and tumor markers AFP, AFP-L3 and DCP based on its personalized diagnosis technology in the diagnosis of liver cancer, liver fibrosis and other cancers.
Proprium Biotech is committed to building an innovative platform combining devices with testing reagents, and realizing the accurate diagnosis of liver diseases and the clinical application of individualized medicine. The founder of Proprium Biotech, Dr. Lin Beiyang, is a well-known expert in the field of systems biology and a pioneer of precision medicine. As early as 2004, he published an article advocating "3P-Medicine" in Science.
Proprium Biotech is located in the Hangzhou Xiasha Economic & Technological Development Area (HEDA), Hangzhou, Zhejiang Province, China. The company was established in 2010 with an initial capital of 62 million yuan (US$ 10 million). The company has a 3000m2 production facility that is certificated by the ISO 13485 International standard, and approved by the Chinese FDA for production of medical devices.
Neovision Capital was founded in 2015. Key founders are from Costone Capital, J.P. Morgan and so on. Leveraging its core team's rich China-operational experiences, international resources and business acumen, the company is actually dedicated to both early and growth-stage investment in the healthcare and TMT sector in China.
In order to leverage its core assets, Neovision Capital actively contributes expertise in essential services including branding, marketing, channel development, overseas expansion, human resources, and finance.